This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiomyopathy	MicroRNA-146a (miR-146a)	<i>In vitro</i> and mouse studies suggest inhibiting miR-146a could help treat peripartum cardiomyopathy (PPCM). In patients with PPCM and in mouse models for the indication, plasma or cardiac levels of miR-146a were higher than those in healthy postpartum controls. In the PPCM mouse models, a locked nucleic acid (LNA) anti-miR-146a increased cardiac function and capillary density and decreased cardiac fibrosis compared with a control oligonucleotide. Future studies could include testing the LNA anti-miR-146a in additional models for PPCM.	Patent and licensing status unavailable	Halkein, J. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online April 24, 2013; doi:10.1172/JCI64365 Contact: Ingrid Struman, University of Liege, Liege, Belgium e-mail: i.struman@ulg.ac.be
<i>SciBX</i> 6(18); doi:10.1038/scibx.2013.438 Published online May 9, 2013				